Pancreatic cancer: are

Lewis, Alexandra R; Valle, Juan W; McNamara, Mairéad G

dc.contributor.author	Lewis, Alexandra R
dc.contributor.author	Valle, Juan W
dc.contributor.author	McNamara, Mairéad G
dc.date.accessioned	2016-10-28T13:32:07Z
dc.date.available	2016-10-28T13:32:07Z
dc.date.issued	2016-08-28
dc.identifier.citation	Pancreatic cancer: are "liquid biopsies" ready for prime-time? 2016, 22 (32):7175-85 World J Gastroenterol	en
dc.identifier.issn	2219-2840
dc.identifier.pmid	27621566
dc.identifier.doi	10.3748/wjg.v22.i32.7175
dc.identifier.uri	http://hdl.handle.net/10541/619984
dc.description.abstract	Pancreatic cancer is a disease that carries a poor prognosis. Accurate tissue diagnosis is required. Tumours contain a high content of stromal tissue and therefore biopsies may be inconclusive. Circulating tumour cells (CTCs) have been investigated as a potential "liquid biopsy" in several malignancies and have proven to be of prognostic value in breast, prostate and colorectal cancers. They have been detected in patients with localised and metastatic pancreatic cancer with sensitivities ranging from 38%-100% using a variety of platforms. Circulating tumour DNA (ctDNA) has also been detected in pancreas cancer with a sensitivity ranging from 26%-100% in studies across different platforms and using different genetic markers. However, there is no clear consensus on which platform is the most effective for detection, nor which genetic markers are the most useful to use. Potential roles of liquid biopsies include diagnosis, screening, guiding therapies and prognosis. The presence of CTCs or ctDNA has been shown to be of prognostic value both at diagnosis and after treatment in patients with pancreatic cancer. However, more prospective studies are required before this promising technology is ready for adoption into routine clinical practice.
dc.language	ENG
dc.language.iso	en	en
dc.rights	Archived with thanks to World journal of gastroenterology	en
dc.title	Pancreatic cancer: are "liquid biopsies" ready for prime-time?	en
dc.type	Article	en
dc.contributor.department	The Christie NHS Foundation Trust, M20 4BX Manchester, United Kingdom	en
dc.identifier.journal	World Journal of Gastroenterology	en
refterms.dateFOA	2018-12-17T14:44:03Z
html.description.abstract	Pancreatic cancer is a disease that carries a poor prognosis. Accurate tissue diagnosis is required. Tumours contain a high content of stromal tissue and therefore biopsies may be inconclusive. Circulating tumour cells (CTCs) have been investigated as a potential "liquid biopsy" in several malignancies and have proven to be of prognostic value in breast, prostate and colorectal cancers. They have been detected in patients with localised and metastatic pancreatic cancer with sensitivities ranging from 38%-100% using a variety of platforms. Circulating tumour DNA (ctDNA) has also been detected in pancreas cancer with a sensitivity ranging from 26%-100% in studies across different platforms and using different genetic markers. However, there is no clear consensus on which platform is the most effective for detection, nor which genetic markers are the most useful to use. Potential roles of liquid biopsies include diagnosis, screening, guiding therapies and prognosis. The presence of CTCs or ctDNA has been shown to be of prognostic value both at diagnosis and after treatment in patients with pancreatic cancer. However, more prospective studies are required before this promising technology is ready for adoption into routine clinical practice.